| 产品名称 | Roflumilast - Daxas | BY 217 | BYK 20869 | B 9302-107 |
| 产品货号 | Axon 2352 CAS [162401-32-3] MF C17H14Cl2F2N2O3MW 403.21 Purity: 100% Soluble in DMSO Description First specific PDE4 inhibitor (IC50 value 0.2 - 4.3 nM for inhibition of PDE4 subtypes) licensed for the treatment of COPD. References Certificates Categories Extra info K.F. Rabe et al. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 2011, 163, 53-67. W. Timmer et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J. Clin. Pharmacol. 2002, 42, 297-303. L.A. Sorbera et al. Roflumilast: antiallergy/antiasthmatic, treatment of COPD, phosphodiesterase 4 inhibitor. Drugs Fut. 2000, 25, 1261-1264. Certificate of Analysis Material Safety Data Sheet Cardiovascular Cell Signaling & Oncology CNS Pain & Inflammation EC 3.1.4.53 PDE First specific PDE4 inhibitor licensed for treatment of COPD Chemical name 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide Parent CAS No. [162401-32-3] Order Size Unit Price Stock 10 mg €90.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
Roflumilast - Daxas | BY 217 | BYK 20869 | B 9302-107Axon 2352 CAS [162401-32-3] MF C17H14Cl2F2N2O3
Description
First specific PDE4 inhibitor (IC50 value 0.2 - 4.3 nM for inhibition of PDE4 subtypes) licensed for the treatment of COPD.
First specific PDE4 inhibitor licensed for treatment of COPD
Chemical name3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide Parent CAS No.[162401-32-3] |
| 产品资料 |
